Literature DB >> 6212116

5-Fluorouracil incorporation in DNA of human breast carcinoma cells.

P P Major, E Egan, D Herrick, D W Kufe.   

Abstract

We have demonstrated previously the presence of 5-fluorouracil (FUra) residues in L1210 DNA. These findings have been extended to the MCF-7 human breast carcinoma cell line. Cesium sulfate gradient centrifugation has been used to separate the MCF-7 RNA and DNA fractions. Alkali and RNase digests have also been used to remove any possible RNA contaminating the DNA fraction. The purified DNA has been analyzed by high-pressure liquid chromatography following digestion to nucleotides and nucleosides. The results demonstrate that FUra residues are detectable in the DNA of these human breast carcinoma cells following exposure to either FUra of 5-fluorodeoxyuridine. Further, the extend of FUra incorporation in both MCF-7 RNA and DNA is similar with either fluorinated pyrimidine. We also demonstrate that the FUra incorporation in DNA from this human cell line can be enhanced by concurrent incubation with thymidine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6212116

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Drug treatment of colorectal cancer. Current status.

Authors:  L Saltz
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  DNA repair following incorporation of 5-fluorouracil into DNA of mouse bone marrow cells.

Authors:  J D Schuetz; H J Wallace; R B Diasio
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  J Phys Chem B       Date:  2016-09-21       Impact factor: 2.991

Review 4.  Chemotherapeutic implications in microsatellite unstable colorectal cancer.

Authors:  Won-Seok Jo; John M Carethers
Journal:  Cancer Biomark       Date:  2006       Impact factor: 4.388

5.  Mismatch repair proficiency and in vitro response to 5-fluorouracil.

Authors:  J M Carethers; D P Chauhan; D Fink; S Nebel; R S Bresalier; S B Howell; C R Boland
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.

Authors:  Xudong He; Yifan Cao; Yun Gu; Hanji Fang; Jieti Wang; Xin Liu; Kunpeng Lv; Kuan Yu; Yuchao Fei; Chao Lin; Hao Liu; Heng Zhang; He Li; Jiejie Xu; Ruochen Li; Hongyong He
Journal:  Ann Surg Oncol       Date:  2021-03-18       Impact factor: 5.344

7.  Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.

Authors:  S Takeda; J Yamashita; H Saito; J Uchida; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 8.  Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.

Authors:  P Chrisp; D McTavish
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

9.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil.

Authors:  Ziyaur Rahman; Kanchan Kohli; Shuang-Qing Zhang; Roop K Khar; Mushir Ali; Naseem A Charoo; Mohammad Tauseef; Areeg A A Shamsher; Noorullah N Mohammed; Michael A Repka
Journal:  J Pharm Pharmacol       Date:  2008-05       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.